Determinants of darunavir cerebrospinal fluid concentrations: Impact of once-daily dosing and pharmacogenetics

AIDS

Volumn 26, Issue 12, 2012, Pages 1529-1533

  Calcagno, Andrea ^a   Yilmaz, Aylin ^b   Cusato, Jessica ^a   Simiele, Marco ^a   Bertucci, Roberto ^a   Siccardi, Marco ^a,c   Marinaro, Letizia ^a   D'Avolio, Antonio ^a   Di Perri, Giovanni ^a   Bonora, Stefano ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

blood brain barrier; darunavir; multidrug resistance protein 2; OATP1A2; once daily; p glycoprotein; pharmacokinetics

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN; PROTEIN SCLO1A2; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MALE; MASS SPECTROMETRY; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BLOOD-BRAIN BARRIER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RITONAVIR; SULFONAMIDES;

EID: 84864279941     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283553619     Document Type: Article

References (10)

1. References Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. October 14, 2011; 1-167. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 15, 2011.
2. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslen M. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25:457-461.
3. Letendre S, Rossi S, Best B, Way L, Ueland S, Grant I, et al. Darunavir concentrations in CSF exceed the median inhibitory concentration. In Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). San Francisco, CA: American Society for Microbiology; 2009. pp. A-1312.
4. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009; 82:A99-A109.
5. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 genetransfected renal LLC-PK1 cell lines. Biol Pharm Bull 2009; 32:1588-1593.
6. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, James E, Liptrott N, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120.
7. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
8. D'Avolio A, Siccardi M, Sciandra M, Baietto L, Bonora S, Trentini L, Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 859:234-240.
9. Marzolini C, Mueller R, Battegay M, Selig A. Permeation of antiretroviral agents across the blood-brain barrier and interactions with efflux drug transporters. In Program and abstracts of the 13th European AIDS Conference. Belgrade, Serbia; 2011: PE6.6/2.
10. Acosta E, Limoli K, Trinh L, Parkin NT, King JR, Weidler J, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. In Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2011. p. 633.